


Medical Safety Information Released in 2024

Medical Safety Information No.206–No.217 was issued from January to December 2024. The full list of bulletins is shown below.


No.	Title
No.206	★ Wrong Quantity Prescribed When Switching from Medicines Brought in at Hospitalization to Internal Prescriptions (1st Follow-up Report)
No.207	★ Use of Blood Purifiers Contraindicated in Patients Receiving ACE Inhibitors
No.208	Medical Safety Information Released in 2023
No.209	★ Use of a Peripheral Vein to Administer an Infusion That Should Be Administered through a Central Vein
No.210	Blockage of Heat and Moisture Exchanger Due to Use in Combination with a Heated Humidifier
No.211	Medical Safety Information Highlighted in Quarterly Reports in 2023
No.212	★ Delayed Discovery of the Migration of an Open Drain into the Body
No.213	Error When Changing Syringe on Syringe Pump
No.214	Incorrect Handling of Open-System Three-Way Stopcock
No.215	★ Hypoglycemia Due to Insulin Administration When Patient's Meals Had Been Stopped
No.216	Ineffective Ventilation of a Patient with a Permanent Tracheostomy
No.217	Guidewire Breakage Due to Combined Use with a Metal Needle

A ★ next to a title indicates that recurrent and similar events were reported during the period to December 31, 2024.

No.209 Use of a Peripheral Vein to Administer an Infusion That Should Be Administered through a Central Vein



No.215 Hypoglycemia Due to Insulin Administration When Patient's Meals Had Been Stopped



Medical Safety Information Released in 2024

◆ These are recurrent and similar events reported in 2024.

No.207 Use of Blood Purifiers Contraindicated in Patients Receiving ACE Inhibitors

Hemoadsorption therapy using Rheocarna was to be administered to a patient with critical limb-threatening ischemia who was admitted to the plastic surgery department. The patient was taking an ACE inhibitor, but as there was no procedure for checking before treatment whether or not patients were taking ACE inhibitors, the medical staff did not check. As the patient's blood pressure fell five minutes after starting the therapy, the nephrologist halted the hemoadsorption therapy.

No.209 Use of a Peripheral Vein to Administer an Infusion That Should Be Administered through a Central Vein

When ordering an infusion for administration through a peripheral vein, the physician erroneously ordered parenteral nutrition. Although the lead nurse knew that parenteral nutrition was a drug that should be administered via a central vein, they forgot that the patient did not have a central venous catheter in place and told the primary nurse to administer the drug. The primary nurse felt that this was strange, but thought that it must be fine to administer in this way because the physician had ordered it, and therefore administered the parenteral nutrition through a peripheral vein.

No.215 Hypoglycemia Due to Insulin Administration When Patient's Meals Had Been Stopped

As the patient was due to undergo a percutaneous transluminal angioplasty (PTA), the physician had ordered that their lunch should be stopped. Nurse A measured the patient's lunchtime blood glucose level and reported to Nurse B that it was 373 mg/dL. Unaware that the patient's lunch had been stopped, Nurse B gave the patient a subcutaneous injection of 4 units of NovoRapid Injection. The patient subsequently developed hypoglycemia, so the nurse administered glucose 10 g orally.

* As part of the Project to Collect Medical Near-Miss/Adverse Event Information (a Ministry of Health, Labour and Welfare grant project), this medical safety information was prepared based on the cases collected in the Project as well as on opinions of the "Comprehensive Evaluation Panel" to prevent the occurrence and recurrence of medical adverse events. See the Project website for details.

<https://www.med-safe.jp/>

* Accuracy of information was ensured at the time of preparation but cannot be guaranteed in the future.

* This information is intended neither to limit the discretion of healthcare providers nor to impose certain obligations or responsibilities on them.



Department of Adverse Event Prevention
Japan Council for Quality Health Care

1-4-17 Kandamisaki-cho, Chiyoda-ku, Tokyo 101-0061 JAPAN

Direct Tel: +81-3-5217-0252 Direct Fax: +81-3-5217-0253

<https://www.med-safe.jp/>